MedTrace Logo

Brazilian Reality of Hepatocellular Carcinoma

NCT06230328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-09-29

No results posted yet for this study

Summary

National, multicenter, retrospective, non-randomized observational study (Real World Evidence-RWE) with the purpose of analyzing the epidemiological profile of Hepatocellular Carcinomas (BCLC A, B or C), clinical management, progression profile and overall survival of castrated patients treated in national oncology care reference centers, within the last 6 years (between 2017 to 2022).

Conditions

  • Hepatocellular Carcinoma
  • Hepatocellular Carcinoma by BCLC Stage
  • Hepatocellular Carcinoma Stage I
  • Hepatocellular Carcinoma Stage II
  • Hepatocellular Carcinoma Stage III

Sponsors & Collaborators

  • Hospital Israelita Albert Einstein

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Diogo Bugano · Hospital Israelita Albert Einstein

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-15
Primary Completion
2024-11-14
Completion
2024-11-14

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06230328 on ClinicalTrials.gov